Biotech-Insider (@BiotechOptions2) header
Biotech-Insider (@BiotechOptions2) profile picture
Joined July 2015
Photo by Biotech-Insider (@BiotechOptions2)Photo by Biotech-Insider (@BiotechOptions2)Photo by Biotech-Insider (@BiotechOptions2)Photo by Biotech-Insider (@BiotechOptions2)Photo by Biotech-Insider (@BiotechOptions2)Photo by Biotech-Insider (@BiotechOptions2)Photo by Biotech-Insider (@BiotechOptions2)Photo by Biotech-Insider (@BiotechOptions2)Photo by Biotech-Insider (@BiotechOptions2)Photo by Biotech-Insider (@BiotechOptions2)
$IBB $XBI $BIB pivoting lower as expected. Even though I'm a long-term bull, can't ignore this downside opportunity with puts.
$ABBV overreaction is an opportunity for longs
$IBB $BIB $XBI looking toppy. Could pull back from resistance here. Hedging long bets wth puts on each.
1
While I'm a long-term #biotech bull, it's tough to ignore the downside opportunity in overbought shares of $IBB $XBI $BIB
Biotech-Insider retweeted
#Biotech companies expected to price #IPO next week: $RUBY Rubius Tx. 9.53M shares at $20-$22/share $ALLK Allakos 6M shares at $15-$17 $CNST Constellation 5.34M shares $14-$16 $REPL Replimune 6.7M shares at $14-$16 $CRNX Crinetics 5M shares at $15-$17
2018 Is a Hot Year for Biotech Startups, IPOs and M&A Activity biospace.com/article/2018-is…
After a pullback $GWPH may have caught support at its 50-day at $149.25. Could it be setting up for a rally into FDA news?
1
3